What have clinical trials taught us about proarrhythmia?

Area of Science:

• Cardiology
• Pharmacology

Background:

• Proarrhythmia, the development or worsening of arrhythmias due to anti-arrhythmic therapy, is a significant clinical concern.
• Sudden arrhythmic death is the most critical manifestation of proarrhythmia.
• Potential mechanisms include afterdepolarizations, repolarization dispersion, conduction slowing, and drug-ischemia interactions.

Purpose of the Study:

• To review the impact of anti-arrhythmic drugs on mortality in high-risk patients, particularly post-myocardial infarction (MI).
• To evaluate the safety and efficacy of specific anti-arrhythmic agents in the context of proarrhythmia.

Main Methods:

• Analysis of recent clinical trials comparing anti-arrhythmic drugs with placebo in post-MI patients.
• Review of studies investigating anti-arrhythmic treatment for atrial fibrillation, especially in patients with structural heart disease.

Main Results:

• Several anti-arrhythmic drugs (encainide, flecainide, moricizine, d-sotalol) have been associated with increased mortality post-MI.
• Increased mortality risk may also occur in atrial fibrillation patients with structural heart disease treated with anti-arrhythmics.
• Amiodarone appears to be safe for treating arrhythmias in post-MI patients, contrasting with other agents.

Conclusions:

• Certain anti-arrhythmic drugs pose a significant mortality risk, necessitating careful patient selection and monitoring.
• Amiodarone demonstrates a favorable safety profile in the post-MI population, warranting further investigation.
• Ongoing studies like CAMIAT and EMIAT are crucial for further understanding anti-arrhythmic drug effects.